Selected research
Industry Research
Amifampridine Industry Research Report 2026
Market perspective
The global Amifampridine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Amifampridine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Amifampridine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Amifampridine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Amifampridine include BioMarin Pharmaceutical, Biosynth AG, BLD Pharm, BroadPharm, CSNpharm, Founder Pharma, Glenmark Pharmaceuticals, Innovapharm and Jacobus Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Amifampridine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Amifampridine Market by Company
BioMarin Pharmaceutical
Biosynth AG
BLD Pharm
BroadPharm
CSNpharm
Founder Pharma
Glenmark Pharmaceuticals
Innovapharm
Jacobus Pharmaceutical
Norris Pharm
Unichem
Wockhardt
Merck
Amifampridine Segment by Type
Generic
Patent
Amifampridine Segment by Application
Myasthenia Gravis
Potassium Channel Blocker
Amifampridine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amifampridine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Amifampridine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amifampridine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Amifampridine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Amifampridine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Amifampridine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Generic
- Patent
Applications
- Myasthenia Gravis
- Potassium Channel Blocker
Companies covered
- BioMarin Pharmaceutical
- Biosynth AG
- BLD Pharm
- BroadPharm
- CSNpharm
- Founder Pharma
- Glenmark Pharmaceuticals
- Innovapharm
- Jacobus Pharmaceutical
- Norris Pharm
- Unichem
- Wockhardt
- Merck
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Amifampridine Market Size (2021-2032)
- 2.2.2 Global Amifampridine Sales (2021-2032)
- 2.2.3 Global Amifampridine Market Average Price (2021-2032)
- 2.3 Amifampridine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Generic
- 2.3.3 Patent
- 2.4 Amifampridine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Myasthenia Gravis
- 2.4.3 Potassium Channel Blocker
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Amifampridine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Amifampridine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Amifampridine Revenue of Manufacturers (2021-2026)
- 3.4 Global Amifampridine Average Price by Manufacturers (2021-2026)
- 3.5 Global Amifampridine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Amifampridine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Amifampridine, Product Type & Application
- 3.8 Global Manufacturers of Amifampridine, Established Date
- 3.9 Global Amifampridine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 BioMarin Pharmaceutical
- 4.1.1 BioMarin Pharmaceutical Company Information
- 4.1.2 BioMarin Pharmaceutical Business Overview
- 4.1.3 BioMarin Pharmaceutical Amifampridine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 BioMarin Pharmaceutical Amifampridine Product Portfolio
- 4.1.5 BioMarin Pharmaceutical Recent Developments
- 4.2 Biosynth AG
- 4.2.1 Biosynth AG Company Information
- 4.2.2 Biosynth AG Business Overview
- 4.2.3 Biosynth AG Amifampridine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Biosynth AG Amifampridine Product Portfolio
- 4.2.5 Biosynth AG Recent Developments
- 4.3 BLD Pharm
- 4.3.1 BLD Pharm Company Information
- 4.3.2 BLD Pharm Business Overview
- 4.3.3 BLD Pharm Amifampridine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 BLD Pharm Amifampridine Product Portfolio
- 4.3.5 BLD Pharm Recent Developments
- 4.4 BroadPharm
- 4.4.1 BroadPharm Company Information
- 4.4.2 BroadPharm Business Overview
- 4.4.3 BroadPharm Amifampridine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 BroadPharm Amifampridine Product Portfolio
- 4.4.5 BroadPharm Recent Developments
- 4.5 CSNpharm
- 4.5.1 CSNpharm Company Information
- 4.5.2 CSNpharm Business Overview
- 4.5.3 CSNpharm Amifampridine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 CSNpharm Amifampridine Product Portfolio
- 4.5.5 CSNpharm Recent Developments
- 4.6 Founder Pharma
- 4.6.1 Founder Pharma Company Information
- 4.6.2 Founder Pharma Business Overview
- 4.6.3 Founder Pharma Amifampridine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Founder Pharma Amifampridine Product Portfolio
- 4.6.5 Founder Pharma Recent Developments
- 4.7 Glenmark Pharmaceuticals
- 4.7.1 Glenmark Pharmaceuticals Company Information
- 4.7.2 Glenmark Pharmaceuticals Business Overview
- 4.7.3 Glenmark Pharmaceuticals Amifampridine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Glenmark Pharmaceuticals Amifampridine Product Portfolio
- 4.7.5 Glenmark Pharmaceuticals Recent Developments
- 4.8 Innovapharm
- 4.8.1 Innovapharm Company Information
- 4.8.2 Innovapharm Business Overview
- 4.8.3 Innovapharm Amifampridine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Innovapharm Amifampridine Product Portfolio
- 4.8.5 Innovapharm Recent Developments
- 4.9 Jacobus Pharmaceutical
- 4.9.1 Jacobus Pharmaceutical Company Information
- 4.9.2 Jacobus Pharmaceutical Business Overview
- 4.9.3 Jacobus Pharmaceutical Amifampridine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Jacobus Pharmaceutical Amifampridine Product Portfolio
- 4.9.5 Jacobus Pharmaceutical Recent Developments
- 4.10 Norris Pharm
- 4.10.1 Norris Pharm Company Information
- 4.10.2 Norris Pharm Business Overview
- 4.10.3 Norris Pharm Amifampridine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Norris Pharm Amifampridine Product Portfolio
- 4.10.5 Norris Pharm Recent Developments
- 4.11 Unichem
- 4.11.1 Unichem Company Information
- 4.11.2 Unichem Business Overview
- 4.11.3 Unichem Amifampridine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Unichem Amifampridine Product Portfolio
- 4.11.5 Unichem Recent Developments
- 4.12 Wockhardt
- 4.12.1 Wockhardt Company Information
- 4.12.2 Wockhardt Business Overview
- 4.12.3 Wockhardt Amifampridine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Wockhardt Amifampridine Product Portfolio
- 4.12.5 Wockhardt Recent Developments
- 4.13 Merck
- 4.13.1 Merck Company Information
- 4.13.2 Merck Business Overview
- 4.13.3 Merck Amifampridine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Merck Amifampridine Product Portfolio
- 4.13.5 Merck Recent Developments
5 Global Amifampridine Market Scenario by Region
- 5.1 Global Amifampridine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Amifampridine Sales by Region: 2021-2032
- 5.2.1 Global Amifampridine Sales by Region: 2021-2026
- 5.2.2 Global Amifampridine Sales by Region: 2027-2032
- 5.3 Global Amifampridine Revenue by Region: 2021-2032
- 5.3.1 Global Amifampridine Revenue by Region: 2021-2026
- 5.3.2 Global Amifampridine Revenue by Region: 2027-2032
- 5.4 North America Amifampridine Market Facts & Figures by Country
- 5.4.1 North America Amifampridine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Amifampridine Sales by Country (2021-2032)
- 5.4.3 North America Amifampridine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Amifampridine Market Facts & Figures by Country
- 5.5.1 Europe Amifampridine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Amifampridine Sales by Country (2021-2032)
- 5.5.3 Europe Amifampridine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Amifampridine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Amifampridine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Amifampridine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Amifampridine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Amifampridine Market Facts & Figures by Country
- 5.7.1 South America Amifampridine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Amifampridine Sales by Country (2021-2032)
- 5.7.3 South America Amifampridine Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Amifampridine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Amifampridine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Amifampridine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Amifampridine Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Amifampridine Sales by Type (2021-2032)
- 6.1.1 Global Amifampridine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Amifampridine Sales Market Share by Type (2021-2032)
- 6.2 Global Amifampridine Revenue by Type (2021-2032)
- 6.2.1 Global Amifampridine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Amifampridine Revenue Market Share by Type (2021-2032)
- 6.3 Global Amifampridine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Amifampridine Sales by Application (2021-2032)
- 7.1.1 Global Amifampridine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Amifampridine Sales Market Share by Application (2021-2032)
- 7.2 Global Amifampridine Revenue by Application (2021-2032)
- 7.2.1 Global Amifampridine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Amifampridine Revenue Market Share by Application (2021-2032)
- 7.3 Global Amifampridine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Amifampridine Value Chain Analysis
- 8.1.1 Amifampridine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Amifampridine Production Mode & Process
- 8.2 Amifampridine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Amifampridine Distributors
- 8.2.3 Amifampridine Customers
9 Global Amifampridine Analyzing Market Dynamics
- 9.1 Amifampridine Industry Trends
- 9.2 Amifampridine Industry Drivers
- 9.3 Amifampridine Industry Opportunities and Challenges
- 9.4 Amifampridine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst